CanSino COVID-19 vaccine

Extended version of the vaccine

CanSino COVID-19 vaccine

Authorization

World Health Organization Emergency Use Listing Procedure

Not authorized.
Expression of interest under assessment [Last checked at WHO EUL official website on 13 January 2022].

European Commission (based upon the recommendation of the European Medicines Agency [EMA])
Not authorized.

China's National Medical Products Administration
Authorized on 15 February 2021 [National Medical Products Administration of China, 2020 ].
Conditional marketing authorization for individuals 18 years of age and over.

Regulatory Authorities of Regional Reference in the Americas

National Administration of Drugs, Foods and Medical Devices (ANMAT, Argentina)
Authorized for emergency use on 10 June 2021 [Ministerio de salud de Argentina, 2021 ].

Brazilian Health Regulatory Agency (ANVISA, Brazil)
Not authorized.

Health Canada
Not authorized.

Public Health Institute (ISP, Chile)
Authorized for emergency use on 7 April 2021 [ISP, 2021 ].
Authorized for individuals between 18 to 60 years of age.

National Institute of Food and Drug Monitoring (INVIMA, Colombia)
Not authorized.

Center for the State Control of Drug Quality (CECMED, Cuba)
Not authorized.

U.S. Food and Drug Administration
Not authorized.

Federal Commission for the Protection against Sanitary Risk (COFEPRIS, Mexico)
Authorized for emergency use on 22 March 2021 [COFREPRIS, 2021 ].

Authorization in other jurisdictions in the Americas
Ecuador
Paraguay

Authorization in other jurisdictions
Hungary
Indonesia
Malaysia
Moldova
Pakistan

The Emergency Use Authorization does not constitute marketing authorization in the country.

Manufacturing

Manufacturers
CanSino Biologics Inc.; China: Manufacturer of recombinant novel Coronavirus vaccine (Adenovirus Type 5 Vector) conditionally approved in 2021. Production capacity of 500 million doses annually [Liu Wei, 2021 ].

Other manufacturers
Petrovax pharmaceutical company; Russia. Production of 10 million doses per month in 2021 [The Moscow Times, 2020 ].

Drugmex; Mexico. The company expects to produce 6.9 million doses between March and June, 2021, and then make 1.2 million shots available per week to fulfill its agreement for 35 million doses this year. Packaging of the vaccine is being produce in Queretaro state [Reuters Staff 1 MIN READ, 2021 ].

Solution Biologics; Malaysia. Produces final filling and packaging of the vaccine for distribution [The Malaysian in sight, 2021 ].

General characteristics

The recombinant coronavirus vaccine (adenovirus type 5 vector) is based on a mature non-recombinant human adenovirus type 5 vector platform, which efficiently expresses SARS-CoV-2 antigen (protein S) in infected cells. It induces a humoral and cellular immune response against the spike protein of SARS-CoV-2 after vaccination, providing protection to its recipients [Feng-Cai Zhu, 2020 ].

The full spike protein gene of SARS-CoV-2 based on the Wuhan-Hu-1 strain was codon-optimized with UpGene software, and the signal peptide was substituted with tPA for increased expression in mammalian cells. The gene was synthesized and cloned into the plasmid of the AdMax adenovirus system (Microbix Biosystem, Canada) by enzyme digestion and ligation. After sequencing, the plasmid with the target gene was transferred into HEK293 cells. The cells were lysed by three freeze-thaw cycles to release the recombinant viruses. The recombinant adenoviruses were monocloned by agarose plaque selection, amplified by serial passage on HEK293 cells, and purified by ion-exchange chromatography and size exclusion. The number of total VP was measured by ultraviolet spectrophotometer analysis [Wu S, 2020 ].

 

Dosage form and ingredients

The pharmaceutical form is a solution for intramuscular injection that is provided in a monodose vial of 0.5 mL, or as a multidose vial of 10 doses of 0.5 mL each.

The vaccine contains the following ingredients
[Ministerio de salud de Argentina, 2021 ], [Ministerio de Salud. Gobierno de Chile., 2021 ]:

Active ingredient
Non-replicating adenovirus Ad5-nCoV ≥4 x 1010 viral particles (PV)

Excipients 
25 mg mannitol
12.5mg sucrose
0.1 mg magnesium chloride
1.5 mg sodium chloride
0.30 mg of N-(2-Hydroxyethyl) piperazine-N´-(2-ethanesulfonic acid)
0.05 mg polysorbate 80
0.75 mg glycerol
459.8 mg of water for the manufacture of injectables

The vaccine does not contain adjuvants or preservatives.

Risk considerations

Clinical experience with the Ad5 platform is mixed. Two studies using an Ad5 vectored HIV-1 vaccine administered found an increased risk of HIV acquisition among vaccinated men. A consensus conference about Ad5 vectors held in 2013 warned that non-HIV vaccine trials that used similar vectors in areas of high HIV prevalence could lead to an increased risk of HIV-1 acquisition in the vaccinated population. The potential mechanism for this increased susceptibility is not completely clear but theories include dampening of HIV immunity, enhancing replication of the AIDS virus, or setting up more target cells for it [Buchbinder SP, 2020 ].

On the other hand, the same effect was not detected in a trial of a recombinant adenovirus type-5 vector-based Ebola vaccine tested in a population in Sierra Leone that had a relatively high HIV prevalence [Zhu FC ]. It is unknown what is the impact on this risk of the genetic engineering process that is applied to Ad5 by different vaccine producers.

Dosing and schedule

Dose-finding studies

CTII-nCoV is a randomized, double-blind, placebo-controlled, phase 2 trial sponsored by Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China and conducted in China. It was registered with ClinicalTrials.gov, NCT04341389 [Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China, 2020 ].

The sample size was 603 volunteers. The inclusion criteria were healthy adults aged 18 years or over. The study evaluated two vaccination schedules, a single injection of 1×10¹¹ or 5×10¹⁰ viral particles per mL, or a placebo injection, which were randomized at a 2:1:1 ratio. Findings showed that seroconversion rates were 96% (95% CI 93–98) and 97% (92–99), respectively of both vaccine schedules, at day 28. Both doses of the vaccine induced significant neutralizing antibody responses to live SARS-CoV-2 [Zhu FC, 2020 ].

CTCOVID-19 is a non-randomized, dose-escalating phase I study sponsored by the Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China and conducted in China. It was registered with ClinicalTrials.gov NCT04313127 [CanSino Biologics Inc., 2020 ].

The sample size was 108 healthy adults aged between 18 and 60 years, that were sequentially allocated to one of three dose groups (5×10¹⁰, 1×10¹¹, and 1.5×10¹¹ viral particles) to receive an intramuscular injection of vaccine. Safety was assessed over 28 days post-vaccination. Specific antibodies were measured with ELISA, and the neutralizing antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralization and pseudovirus neutralization tests. Results showed, ELISA antibodies and neutralizing antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination [Zhu FC, 2020 ].

There is no data available on the interchangeability of the CanSino COVID-19 vaccine with other COVID-19 vaccines to complete the vaccination series.

There is no evidence yet about the effects of the coadministration of the CanSino COVID-19 vaccine with other vaccines included in routine vaccination programs.

Indications and contraindications

Indications

CanSino COVID-19 vaccine is indicated for adult individuals 18 years of age and over [Ministerio de salud de Argentina, 2021 ].

Contraindications

CanSino COVID-19 vaccine is contraindicated in individuals with a known history of a severe allergic reaction to any component of the vaccine [Ministerio de salud de Argentina, 2021 ]. (See the list of ingredients under 'General characteristics' in the extended version).

Precautions

Severe allergic reaction (e.g., anaphylaxis) to a previous dose of any vaccine (not including CanSino COVID-19 vaccine ).

Severe allergic reaction (e.g., anaphylaxis) to an injectable medication.

Vaccination should be postponed in individuals suffering from acute severe febrile illness, or acute infection [Gobierno de México, 2021 ].

The available data of CanSino COVID-19 vaccine on pregnant females are insufficient to assess vaccine efficacy in pregnancy since no clinical trial evaluating vaccines to prevent COVID-19 has included pregnant females. The vaccine should only be given to pregnant females if risks outweigh the benefit [Gobierno de México, 2021 ].

The available data of CanSino COVID-19 vaccine on lactating females are insufficient to assess whether the vaccine is excreted in human milk or if there is any associated risk.

The available data on CanSino COVID-19 vaccine on children are insufficient to assess vaccine efficacy since no clinical trial evaluating vaccines to prevent COVID-19 has included children [Gobierno de México, 2021 ].

The interaction of concomitant administration of CanSino COVID-19 vaccine with other vaccines has not been studied [Gobierno de México, 2021 ].

There should be a minimum interval of 14 days between the administration of this vaccine with any other vaccine in the immunization schedule, until data on co-administration with other vaccines are available.

Vaccination may be offered regardless of a person’s history of symptomatic or asymptomatic SARS-CoV-2 infection.

Although there are currently no medical contraindications on the vaccinating of a person with COVID-19, it is recommended to defer all vaccinations until complete recovery [PAHO, 2020 ].

Although there are currently no contraindications on the vaccinating of a person who has had contact with a COVID-19 case, it is recommended to defer vaccination until the quarantine has been completed (14 days after the last exposure) [PAHO, 2020 ].


Close observation for at least 30 minutes is recommended following vaccination.

Close observation for at least 30 minutes is recommended following vaccination.

Clinical studies - general characteristics

Randomized trials

CTII-nCoV was a randomized phase 2 trial (registered with the number NCT04341389 [Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China, 2020 ]), sponsored by the Institute of Biotechnology and the Academy of Military Medical Sciences, that it was conducted in China. The aim of the study was to evaluate two vaccination schedules. It was first registered in April 2020 and enrolled 603 participants, aged 18 years or older, that receive the vaccine or placebo vaccine in a 2:1:1 ratio. The study was completed in January 2021. Results showed 96% and 97% efficacy on the different vaccinations schemes in the trial [Zhu FC, 2020 ].

AMMS85-2004 was a ongoing randomised, single-center, open-label, phase 1 trial sponsored by Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China, and conducted China. It was registered in September 2020 with trial registry number NCT04552366. The trial included healthy adults aged 18 years and older. The sample size was 230. The mean age of the participants was 36 years in the HDmu group, 29 years in the LDmu and 2Dim groups, and 27 years MIX and 1Dim group. The proportion of females was 50%.

Participants were randomly assigned in a 1:1:1:1:1 ratio to one of following groups:

-Initial high dose (HDmu group) of Ad5-nCoV vaccine on day 0, followed by a booster on day 28

-Low dose (LDmu group) of Ad5-nCoV vaccine on day 0, followed by a booster on day 28. -An initial intramuscular vaccine on day 0, followed by an aerosolized booster vaccine on day 28 (MIX group).

-One dose (1Dim group) of Ad5-nCoV on day 0.

-Two doses (2Dim group) of Ad5-nCoV on day 0.[Wu, Shipo, 2021 ]

JSVCT116 was a phase 4, randomized, controlled, observer-blinded trial sponsored by Jiangsu Province Centers for Disease Control and Prevention and conducted China. It was registered in May 2021 with trial registry number NCT04892459. The trial included healthy adults 18-59 years of age. The sample size was 300. The mean age of the participants was ranged in age from 42-45 between groups years. The proportion of women was ranged from 37%-47% between groups.

Participants were randomly assigned in a 1:1 ratio to one of the following groups:

- Two doses Coronavac and a booster dose of Convidecia

- Two doses Coronavac and a booster dose of CoronaVac 

- One dose Coronavac and a booster dose of Convidecia

- One dose Coronavac and a booster dose of CoronaVac [Jingxin Li, 2021 ].

 

Ongoing randomized trials

Prometheus_Rus is an ongoing phase III">phase III clinical trial (registered with the number NCT04540419 [NPO Petrovax, 2020 ]) sponsored by NPO Petrovax that is being conducted in Russia. It was first registered on September 11, 2020 and plans to enroll 500 healthy adults aged 18 to 85 years old that will receive Ad5-nCoV single dose vaccine or placebo vaccine. It is expected to run until July 31, 2021.

Halperin SA et al is an ongoing phase III">phase III trial (registered with the number ChiCTR2100044249 [Canadian Center for Vaccinology Dalhousie University/IWK Health Centre , 2021 ]) sponsored by Canadian Center for Vaccinology Dalhousie University/IWK Health Centre, that is being conducted in Pakistan, Argentina, Rusia, Chile and Mexico. It was first registered in March, 2021 and plans to enroll 40000 adults of 18 years of age and more that will receive 0.5mL of intramuscular vaccine or placebo vaccine. It is expected to run until February, 2022.

Ad5-nCoV-2020003 is an ongoing Phase 1/2 trial (registered with the number NCT04398147 [CanSino Biologics Inc., 2020 ]) sponsored by CanSino Biologics Inc., that is being conducted in Canada. It was first registered in August, 2020 and plans to enroll 696 healthy adults from 18 to <55, and 65 to <85 years of age that will receive recombinant novel Coronavirus vaccine (Adenovirus Type 5 Vector) or placebo vaccine. It is expected to run until December, 2021.

JSVCT118 is an ongoing single-center, randomized and double-blinded trial (registered with the number NCT04916886) sponsored by CanSino Biologics Inc. that is being conducted in China [CanSino Biologics Inc., 2021 ]. It was first registered in June 2021 and plans to enroll 2016 individuals 6-59 years of age that will receive Ad5-nCoV. It is expected to run for until August 2022.

FH-58 is an ongoing double-blind, randomized, multi-centre, placebo-controlled, clinical trial (registered with the number NCT05005156) sponsored by Fundación Huésped that is being conducted in Argentina [Fundación Huésped, 2021 ]. It was first registered in August 2021 and plans to enroll 876 participants 18 years of age and older, living with HIV that will receive Ad5-nCoV or placebo. It is expected to run for until September 2022.

 

Other studies providing efficacy or safety data

CTCOVID-19 is a non-randomized, dose-escalating phase I study on 108 healthy adults aged between 18 and 60 years, that were sequentially allocated to one of three dose groups (5.0 × 1010, 1.0 × 1011, and 1.5 × 1011 viral particles) to receive an intramuscular injection of vaccine. The study was conducted in China from March 2020 to December 2020. The results were published in a scientific journal on May 22, 2020 [Zhu FC, 2020 ].

Methods used to assess efficacy

There are no phase 3 randomized trials that have yet reported outcome data.

Safety evaluation methods

There are no phase 3 randomized trials that have yet reported outcome data.

Vaccine efficacy and effectiveness

Efficacy of preclinical studies on the vaccine

Results of geometric mean titers in mice showed that Ad5-nCoV had good immunogenicity and the value of antibody increased with the time of vaccination in a dose-dependent manner. Fourteen days after the injection, the levels of IFN-γ, TNF-α and IL-2 expressed by CD8+ T cells and CD4+ T cells in the vaccine groups were significantly higher than those in the control group (P<  0.001). It can be suggested that the recombinant novel coronavirus vaccine (adenovirus type 5 vector) can induce strong specific cellular immune responses in mice [Feng-Cai Zhu, 2020 ].

Studies in guinea pigs, showed that the anti-S protein IgG antibodies were detected 14 and 28 days after single vaccination. Results showed that the vaccine had good immunogenicity [Feng-Cai Zhu, 2020 ].

24 ferrets were randomly assigned to three groups: high dose vaccine group (2.0 × 1010 vp), low dose vaccine group (2.0 × 109 vp) and control group. Each ferret was injected intramuscularly once at day 0. The live SARS-CoV-2 virus was challenged at day 14 after vaccination. The results showed that the recombinant adenovirus vector vaccine could induce neutralizing antibodies within 2 weeks, and the replication level of upper respiratory tract virus in immunized animals was significantly lower than that in control animals. The results showed that the vaccine had good immunogenicity and could induce immune protection against upper respiratory tract SARS-CoV-2 infection [Feng-Cai Zhu, 2020 ].

12 rhesus monkeys were randomly assigned to three groups: high dose vaccine group (2.0 × 1011 vp), low dose vaccine group (5.0 × 1010 vp), and control group. Each rhesus monkey was injected intramuscularly once at day 0, and then the animal was challenged with the live SARS-CoV-2 virus at day 14 after vaccination. After challenge, there was no significant increase in body temperature in the vaccine groups, and a high level of viral load was detected in pharynx swab, anal swab, and lung tissue. Results suggest that high-dose and low-dose of vaccine has a certain protective effect [Feng-Cai Zhu, 2020 ].

Efficacy of the vaccine in clinical trials

Main immunogenicity outcomes

The primary endpoints for immunogenicity were the geometric mean titers (GMTs) of RBD-specific ELISA antibody responses and neutralizing antibody responses against live virus or pseudovirus at day 28 post-vaccination. A total of 508 participants were randomly assigned to vaccine or placebo, 253 participants were assigned to the 1 × 10^11 viral particles dose group, 129 to the 5 × 10^10 viral particles dose group, and 126 to the placebo group. The mean age of the participants was 39.7 years (range 18-83 years old).
RBD-specific ELISA antibody responses induced by the CanSino COVID-19 vaccine were detected from day 14 onwards, with GMTs of 94.5% (95% CI 80.5-110.8) and 85% (66-110) in the 1×10^11 and 5×10^10 viral particles dose groups, respectively. At day 28, the antibodies peaked at 657% (575.2-749.2) in the 1×10^11 viral particles dose group and 571% (467.6-697.3) in the 5×10^10 viral particles dose group. Seroconversion rates were 96% (95% CI 93-98), this means 244 of 253 participants in the 1×10^11 viral particles dose group and 97% (95% CI 92-99), this means 125 of 129 participants in the 5×10^10 viral particles dose group, at day 28 post-vaccination [Zhu FC, 2020 ] "

Both vaccine doses induced significant neutralizing antibody responses to live SARS-CoV-2, with GMTs of 19.5% (95% CI 16.8-22.7) and 18.3% (95% CI 14.4-23.3) in participants in the 1×10^11 and 5×10^10 viral particles dose groups, respectively, at day 28 post-vaccination. Seroconversion of the neutralizing antibody responses to live SARS-CoV-2 occurred in 59% (95% CI 52-65), this means 148 of 253 participants receiving the 1×10^11 viral particles dose, and in 47% (95% CI 39-56), this means 61 of 129 participants receiving the 5×10^10 viral particles dose 28 days post-vaccination. No significant differences were observed between the two-dose groups in the neutralizing antibody responses to live virus [Zhu FC, 2020 ].

Main efficacy outcomes of CanSino COVID-19 vaccine

Contracting COVID-19

The risk of contracting any COVID-19 infection has not yet been reported, so it was not possible to estimate the effect for this outcome.


Contracting severe COVID-19

The risk of contracting severe COVID-19 infection has not yet been reported, so it was not possible to estimate the effect for this outcome.


Efficacy and effectiveness of the vaccine in subgroups

Sex

Randomized trials

The proportion of female in the CTII-nCoV was 50.3% (192 out of 382 participants) [Zhu FC, 2020 ].

Male and female participants who received the vaccine showed similar RBD-specific ELISA antibody and neutralizing antibody responses post-vaccination.

 

Age

Randomized trials

The proportion of participants 18-44 years of age in the CTII-nCoV was 60.7% (232 out of 382 participants) [Zhu FC, 2020 ].

The proportion of participants 45-54 years of age in the CTII-nCoV was 25.9% (99 out of 382 participants) [Zhu FC, 2020 ].

The proportion of participants >55 years of age in the CTII-nCoV was 13.4% (51 out of 382 participants) [Zhu FC, 2020 ].

Age stratified analysis found that participants aged 55 years or older were associated with relatively low antibody responses in both dose groups post-vaccination, particularly in terms of neutralizing antibodies to live viruses. Increasing age was found to be a negative impact factor on the RBD-specific ELISA antibody (p = 0.0018), and neutralizing antibody responses to live virus (p<0.001).

The single-center, randomized and double-blinded trial JSVCT118 is currently evaluating the efficacy/safety/Immunogenicity of the vaccine in individuals 6-59 years of age [CanSino Biologics Inc., 2021 ].

 

Children and adolescents

Randomized trials

Children were excluded from the CTII-nCoV trial, so no data are available for this subgroup [Zhu FC, 2020 ].

 

Pregnancy

Randomized trials

Pregnant females were excluded from the CTII-nCoV trial, so no data are available for this subgroup [Zhu FC, 2020 ].

 

Breast-feeding

Randomized trials

Breastfeeding females were excluded from the CTII-nCoV trial, so no data are available for this subgroup [Zhu FC, 2020 ].

 

Immunocompromised persons

Randomized trials

Immunocompromised participants were excluded from the CTII-nCoV trial, so no data are available for this subgroup [Zhu FC, 2020 ].

The double-blind, randomized, multi-center, placebo-controlled, clinical trial FH-58 is currently evaluating the immunogenicity of the vaccine in participants 18 years of age and older, living with HIV [Fundación Huésped, 2021 ].

 

Other data on vaccine efficacy and effectiveness

Main effectiveness outcomes of CanSino COVID-19 vaccine (Other studies)

Contracting COVID-19

No studies reported or assessed this outcome.

Contracting severe COVID-19

No studies reported or assessed this outcome.

Transmission

No studies reported or assessed this outcome.


SARS-CoV-2 variants

Immunogenicity outcomes

To date, no studies assessed the vaccine effectiveness outcomes against SARS-CoV-2 variants.

Randomized trials

To date, no studies assessed the vaccine effectiveness outcomes against SARS-CoV-2 variants.

Other studies

To date, no studies assessed the vaccine effectiveness outcomes against SARS-CoV-2 variants.


Booster dose

Immunogenicity outcomes 

To date, no studies assessed the vaccine immunogenicity outcomes against SARS-CoV-2 variants.


Heterologous vaccine regimens

Immunogenicity outcomes

JSVCT116 is a phase 4 randomised trial sponsored by Jiangsu Province Centers for Disease Control and Prevention and conducted in China. The study included 101 participants: 51 heterologous regimen (one dose of Sinovac + one dose of Cansino); 50 homologous regimen (two doses of Sinovac). The immunogenicity was assessed by the geometric mean titres (GMTs) of neutralizing antibodies against live SARS-CoV-2 virus at 14 days after the booster vaccination. Result showed the heterologous immunization with Cansino induced higher live viral neutralizing antibodies than did the homogeneous immunization with Sinovac[Jingxin Li, 2021 ].


Heterologous-booster regimens

Immunogenicity outcomes

JSVCT116 is a phase 4 randomised trial sponsored by Jiangsu Province Centers for Disease Control and Prevention and conducted in China. The study included 198 participants: 96 two doses of Sinovac + booster dose of Cansino; 102 two doses of Sinovac + booster dose of Sinovac. The immunogenicity was assessed by the geometric mean titres (GMTs) of neutralizing antibodies against live SARS-CoV-2 virus at 14 days after the booster vaccination. Result showed the heterologous immunization with Cansino induced higher live viral neutralizing antibodies than did the homogeneous immunization with Sinovac [Jingxin Li, 2021 ].

Safety of the vaccine

Safety of the vaccine in preclinical studies

Toxicity experiments performed in rats showed no changes in all animal indexes, including clinical observation, body weight and food intake. The recombinant novel coronavirus vaccine (adenovirus vector) was given to each rat by intramuscular injection at one dose, and no toxic reaction was observed. The maximum tolerated dose (MTD) of each rat was ≥ 0.5×10 ^ 11 vp/dose [Feng-Cai Zhu, 2020 ].

Toxicity experiments of repeated intramuscular injection in cynomolgus monkeys were performed. During the experiment, no deaths were observed, and no abnormal reaction related to drug administration was found in clinical observation. Moreover, no allergic reaction symptoms were found in the clinical observation period after the two administration schedules. During the experiment, animals in the low and high dose groups (1 dose and 3 doses), showed normal clinical parameters regarding body weight and weight gain, body temperature, ECG waveform, and blood pressure parameters. In addition, clinicopathology, T lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+), serum cytokines (IL-2, IL-4, IL-5, IL-6, TNF- α, IFN-γ), C-reactive protein and serum complement (C3, C4) did not change significantly or showed no abnormal changes in toxic physiology during the 4 weeks follow-up period [Feng-Cai Zhu, 2020 ].

Safety of the vaccine in clinical trials

Key messages

CanSino COVID-19 vaccine increases the risk of any adverse event

Main efficacy outcomes of CanSino COVID-19 vaccine

Any adverse event (mean follow up 28 days)

The relative risk of any adverse event in the group that received CanSino COVID-19 vaccine versus the group that received the control vaccine was 1.59 (95% CI 1.32 to 1.92). This means CanSino COVID-19 vaccine increased the risk of any adverse event in 59%, compared with the control vaccine.

Figure - Forest plot of risk ratio meta-analysis. Outcome: any adverse event. Comparison: CanSino COVID-19 vaccine versus control vaccine

In the trial identified in this review, 61 people not receiving CanSino COVID-19 vaccine out of 126 presented this outcome (484 per 1000) versus 294 out of 382 in the group that did receive it (770 per 1000). In other words, 286 more people per 1000 did not develop the outcome because of the vaccine. This is the same as saying that the intervention led to an absolute risk increase of 28.6%, or that the intervention increased the risk of any adverse event by 28.6 percentage points. Another way of presenting the same information about the absolute effects is the number needed to treat for an additional beneficial/harmful outcome (NNTB/H), the number of participants who need to receive the intervention for one of them to experience the outcome. In this case, the NNH is 3.

Applying the GRADE approach [The GRADE Working Group, 2013 ], we assessed the certainty of the evidence for this outcome as high certainty evidence.

Serious adverse events

No serious adverse events were documented in the available trail within 28 days. Therefore, it is not possible to estimate the effect for this outcome [Zhu FC, 2020 ].

Summary of findings (iSoF)

Safety of the vaccine in subgroups

Sex

Randomized trials

The proportion of female in the CTII-nCoV was 50.3% (192 out of 382 participants) [Zhu FC, 2020 ].

The proportion of females that experienced adverse effects with CanSino COVID-19 vaccine versus the group that received placebo vaccine was not reported in detail.

 

Age

Randomized trials

The proportion of participants 18-44 years of age in the CTII-nCoV was 60.7% (232 out of 382 participants) [Zhu FC, 2020 ].

The proportion of participants 45-54 years of age in the CTII-nCoV was 25.9% (99 out of 382 participants) [Zhu FC, 2020 ].

The proportion of participants >55 years of age in the CTII-nCoV was 13.4% (51 out of 382 participants) [Zhu FC, 2020 ].

Increasing age was statistically associated with a significantly lower occurrence of fever post-vaccination (p<0.001).

 

Children and adolescents

Randomized trials

Children were excluded from the CTII-nCoV trial, so no data are available for this subgroup [Zhu FC, 2020 ].

 

Pregnancy

Randomized trials

Pregnant females were excluded from the CTII-nCoV trial, so no data are available for this subgroup [Zhu FC, 2020 ].

 

Breast-feeding

Randomized trials

Breastfeeding females were excluded from the CTII-nCoV trial, so no data are available for this subgroup [Zhu FC, 2020 ].

 

Immunocompromised persons

Randomized trials

Immunocompromised participants were excluded from the CTII-nCoV trial, so no data are available for this subgroup [Zhu FC, 2020 ].

Safety of the vaccine post-authorization

Post-authorization studies

Comparative studies

No comparative study reported or evaluated this outcome.

Non-comparative studies

None available.

Monitoring

WHO recommends the following research and post-authorization monitoring activities:

Safety surveillance and monitoring
- Serious adverse events, anaphylaxis and other serious allergic reactions, Bell’s palsy, cases of multisystem inflammatory syndrome following vaccination, cases of COVID-19 following vaccination that result in hospitalization or death.

Vaccine effectiveness
− Vaccine effectiveness over time and whether protection can be prolonged by booster doses.
− Studies to investigate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding.
− Assessment and reporting of vaccination failures and virus sequence information.

Subgroups
− Prospective studies on the safety of COVID-19 vaccine in pregnant and lactating females.
− Randomized controlled trials on efficacy and safety of vaccination in children below the age of 18 years.
− Safety data on vaccination in immunocompromised people, including patients living with HIV and autoimmune disease.

Vaccination logistics
− Immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal vaccines, to adults and older persons.
− Safety, immunogenicity, and impact of a delayed second dose, as currently implemented by certain countries.
− Stability of the vaccine under alternative cold-chain distribution and storage conditions.
− Effectiveness of the proposed strategies for the prevention and management of anaphylactic reactions.
− Interchangeability studies within and across COVID-19 vaccine platforms.

References

[National Medical Products Administration of China, 2020] National Medical Products Administration of China. China grants conditional approval for first COVID vaccine. 2020; National Medical Products Administration of China. China grants conditional approval for first COVID vaccine. 2020;
[Ministerio de salud de Argentina, 2021] Ministerio de salud de Argentina. Resolución 1671/2021. RESOL-2021-1671-APN-MS. Report. 2021; Ministerio de salud de Argentina. Resolución 1671/2021. RESOL-2021-1671-APN-MS. Report. 2021;
[ISP, 2021] ISP. ISP aprueba uso de emergencia e importación de la vacuna Cansino para combatir COVID-19. 2021; ISP. ISP aprueba uso de emergencia e importación de la vacuna Cansino para combatir COVID-19. 2021;
[COFREPRIS, 2021] COFREPRIS. COFEPRIS AUTHORIZES THE EMERGENCY USE OF THE CANSINO VACCINE FOR PACKAGED LOTS IN MEXICO. Press release - COFEPRIS - 22 de marzo de 2021. 2021; COFREPRIS. COFEPRIS AUTHORIZES THE EMERGENCY USE OF THE CANSINO VACCINE FOR PACKAGED LOTS IN MEXICO. Press release - COFEPRIS - 22 de marzo de 2021. 2021;
[Liu Wei, 2021] Liu Wei. Annual production of Chinese single-shot COVID-19 vaccine can reach 500m. 2021; Liu Wei. Annual production of Chinese single-shot COVID-19 vaccine can reach 500m. 2021;
[The Moscow Times, 2020] The Moscow Times. Russian Recruits Show ‘No Side Effects’ in Chinese Coronavirus Vaccine Trials. 2020. The Moscow Times. Russian Recruits Show ‘No Side Effects’ in Chinese Coronavirus Vaccine Trials. 2020.
[Reuters Staff 1 MIN READ, 2021] Reuters Staff 1 MIN READ. China's CanSino says first vaccines packaged in Mexico will be ready in March. 2021; Reuters Staff 1 MIN READ. China's CanSino says first vaccines packaged in Mexico will be ready in March. 2021;
[The Malaysian in sight, 2021] The Malaysian in sight. Malaysia to receive CanSino vaccine this month. 2021; The Malaysian in sight. Malaysia to receive CanSino vaccine this month. 2021;
[Feng-Cai Zhu, 2020] Feng-Cai Zhu, Xu-Hua Guan, Jian-Ying Huang et al. A randomized, double-blind, placebo-controlled phase II clinical trial of the recombinant novel coronavirus vaccine (adenovirus type 5 vector) in healthy adults aged 18 years and above in China. Trial prot Feng-Cai Zhu, Xu-Hua Guan, Jian-Ying Huang et al. A randomized, double-blind, placebo-controlled phase II clinical trial of the recombinant novel coronavirus vaccine (adenovirus type 5 vector) in healthy adults aged 18 years and above in China. Trial prot
[Wu S, 2020] Wu S, Zhong G, Zhang J et al. A single dose of an adenovirus-vectored vaccine provides complete protection of the upper and lower respiratory tracts against SARS-CoV-2 challenge. ResearchSquare. 2020; Wu S, Zhong G, Zhang J et al. A single dose of an adenovirus-vectored vaccine provides complete protection of the upper and lower respiratory tracts against SARS-CoV-2 challenge. ResearchSquare. 2020;
[Ministerio de salud de Argentina, 2021] Ministerio de salud de Argentina. Manual del Vacunador Vacuna CONVIDECIA. 2021; Ministerio de salud de Argentina. Manual del Vacunador Vacuna CONVIDECIA. 2021;
[Ministerio de Salud. Gobierno de Chile., 2021] Ministerio de Salud. Gobierno de Chile.. FICHA VACUNA CONTRA SARS-COV-2 VACUNA CONVIDECIA - LABORATORIO CANSINO BIOLOGICALS INC. 2021; Ministerio de Salud. Gobierno de Chile.. FICHA VACUNA CONTRA SARS-COV-2 VACUNA CONVIDECIA - LABORATORIO CANSINO BIOLOGICALS INC. 2021;
[Buchbinder SP, 2020] Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5 vectored vaccines: a cautionary tale. Lancet (London, England). 2020;396(10260):e68-e69. Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5 vectored vaccines: a cautionary tale. Lancet (London, England). 2020;396(10260):e68-e69.
[Zhu FC] Zhu FC, Wurie AH, Hou LH et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, Englan Zhu FC, Wurie AH, Hou LH et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, Englan
[Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China, 2020] Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China. A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector). clinicaltrials.gov. 2020; Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China. A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector). clinicaltrials.gov. 2020;
[Zhu FC, 2020] Zhu FC, Guan XH, Li YH et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020;396(10249):479-4 Zhu FC, Guan XH, Li YH et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020;396(10249):479-4
[CanSino Biologics Inc., 2020] CanSino Biologics Inc.. A Phase I Clinical Trial in 18-60 Adults. clinicaltrials.gov. 2020; CanSino Biologics Inc.. A Phase I Clinical Trial in 18-60 Adults. clinicaltrials.gov. 2020;
[Zhu FC, 2020] Zhu FC, Li YH, Guan XH et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet (London, England). 2020;395(10240):1845-1854. Zhu FC, Li YH, Guan XH et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet (London, England). 2020;395(10240):1845-1854.
[Gobierno de México, 2021] Gobierno de México. Guía Técnica para la aplicación de la Vacuna Recombinante de Vector de Adenovirus Tipo 5 contra el Virus SARS-CoV-2 de Cansino Biologics. GUÍA TÉCNICA PARA LA APLICACIÓN DE LA VACUNA CANSINO CONTRA EL VIRUS SARS-CoV-2. 2021; Gobierno de México. Guía Técnica para la aplicación de la Vacuna Recombinante de Vector de Adenovirus Tipo 5 contra el Virus SARS-CoV-2 de Cansino Biologics. GUÍA TÉCNICA PARA LA APLICACIÓN DE LA VACUNA CANSINO CONTRA EL VIRUS SARS-CoV-2. 2021;
[PAHO, 2020] PAHO. The Immunization Program in the Context of the COVID-19 Pandemic, 26 March 2020. PAHO/FPL/IM/COVID-19/20-0005. 2020; PAHO. The Immunization Program in the Context of the COVID-19 Pandemic, 26 March 2020. PAHO/FPL/IM/COVID-19/20-0005. 2020;
[Wu, Shipo, 2021] Wu, Shipo, Huang, Jianying, Zhang, Zhe et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. The L Wu, Shipo, Huang, Jianying, Zhang, Zhe et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. The L
[Jingxin Li, 2021] Jingxin Li, Lihua Hou, Xiling Guo et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv. 2021; Jingxin Li, Lihua Hou, Xiling Guo et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv. 2021;
[NPO Petrovax, 2020] NPO Petrovax. Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19. clinicaltrials.gov. 2020; NPO Petrovax. Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19. clinicaltrials.gov. 2020;
[Canadian Center for Vaccinology Dalhousie University/IWK Health Centre , 2021] Canadian Center for Vaccinology Dalhousie University/IWK Health Centre. Global phase III trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in adults 18 years of age and older. Chinese Clinical Trial Registry. 2021; Canadian Center for Vaccinology Dalhousie University/IWK Health Centre. Global phase III trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in adults 18 years of age and older. Chinese Clinical Trial Registry. 2021;
[CanSino Biologics Inc., 2020] CanSino Biologics Inc.. Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Canada. clinicaltrials.gov. 2020; CanSino Biologics Inc.. Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Canada. clinicaltrials.gov. 2020;
[CanSino Biologics Inc., 2021] CanSino Biologics Inc.. A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups. clinicaltrials.gov. 2021; CanSino Biologics Inc.. A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups. clinicaltrials.gov. 2021;
[Fundación Huésped, 2021] Fundación Huésped. Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector, Ad5-nCoV) in Adults Living With HIV. clinicaltrials.gov. 2021; Fundación Huésped. Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector, Ad5-nCoV) in Adults Living With HIV. clinicaltrials.gov. 2021;
[The GRADE Working Group, 2013] The GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. Schünemann H, Bro?ek J, Guyatt G, Oxman A, editors. 2013; The GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. Schünemann H, Bro?ek J, Guyatt G, Oxman A, editors. 2013;
Back to dashboard